Cash Is King 👑

Cash Is King

On Sunday, Gilead announced that it will acquire biotech company Immunomedics for a whopping $21 billion dollars in a deal that will augment Gilead’s portfolio of cancer treatments. 

Immunomedics is known for its drug Trodelvy. Trodelvy is an FDA-approved treatment for metastatic triple-negative breast cancer. Gilead CEO Daniel O’day stated “Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat, we will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments.” Gilead has the chance to innovate and improve the drug to ultimately provide better treatment for patients.

Gilead said it will be acquiring Immunomedics shares at $88 each! This equates to a total value of $21 billion dollars. The company has issued $6 billion dollars of newly issued debt to pay for the deal and the remaining $15 billion will be funded through about $15 billion in cash on hand.

As the pandemic continues to weaken demand for some drugs, the availability of cancer treatments is still one you can unfortunately bank on. Gilead’s sales fell 10% during the second quarter so the need to diversify its oncology portfolio has never been greater.

It’s hard to say what this means for the company in the short term. Gilead’s ability to adapt as the pandemic ensues is critical to the company’s long term health. Investors will have to see if Gilead succeeds in developing fresh new ways to use Trodelvy to save more lives.

I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.

Share:

More Posts

Load More
Get your daily Invstr Crunch

Get the market news and updates you need, delivered to your inbox or available on our daily podcast.

Facebook Twitter Youtube Instagram Snapchat Tiktok
learn
products
plan
Who we are
blog

Risk Disclosure:

Invstr is not a bank and banking services are provided by Vast Bank, N.A.

Brokerage and Banking services are currently only available to U.S. residents.

Invstr app and web services are provided by Invstr Ltd. Advisory services are provided by Invstr Financial LLC, an investment adviser registered with the Securities Exchange Commission (SEC) details of which can be obtained here. Securities brokerage and custody services are provided by Apex Clearing, a broker dealer registered with the SEC and a member of FINRA and SIPC. There is no bank guarantee on securities and securities may lose value.

Investing involves risk and can lead to losses. Past performance does not guarantee future results.

Invstr app and web services are provided by Invstr Ltd. Invstr+ advisory services are provided by Invstr Financial LLC, an investment adviser registered with the Securities Exchange Commission (SEC). Securities brokerage and custody services are provided by Apex Clearing, a broker dealer registered with the SEC and a member of FINRA and SIPC. There is no bank guarantee on securities and securities may lose value. Vast Bank N.A. a nationally chartered bank and member of the FDIC, provides the banking products, including the products and services related to digital asset accounts. As with any asset, the value of Digital assets can go up or down and there can be a substantial risk that you lose money buying or holding digital assets. You should carefully consider whether trading or holding Digital assets is suitable for you in light of your financial condition. Your digital account does not support wallet to wallet transferring of your digital assets (i.e. cryptocurrencies) outside the platform. Any Digital Assets in your digital asset account are not insured by any government entities, including but not limited to FDIC or SIPC. The Invstr Visa® Debit Card is issued by Vast Bank, N.A. pursuant to a license from Visa U.S.A Inc and may be used everywhere Visa debit cards are accepted. Invstr Ltd, Invstr Financial LLC and Invstr Securities Ltd are subsidiaries of Marketspringpad Holdings (collectively “Invstr”) and Invstr is solely responsible for the application services and website content.

Watchlists provided when users first access the service are not a recommendation to invest. Instead they are provided to help users better navigate the service. Users are free to edit and create their own watchlists. From time to time, Invstr will suggest instruments solely based on an individual’s interest and the interest levels of the Invstr community.The statistical and portfolio builder models generated by Invstr do not reflect actual investment results and are not guarantees of future results.Comments provided by Invstr leaders, influencers or members of the Invstr Community are not recommendations and should not be construed as such.Invstr does not endorse the content or the positions posted by them. Their investment approach, and that of the models provided by Invstr, may be different from yours and may not be appropriate for you.